CU20200110A7 - Péptidos para el tratamiento de infecciones respiratorias de origen viral - Google Patents

Péptidos para el tratamiento de infecciones respiratorias de origen viral

Info

Publication number
CU20200110A7
CU20200110A7 CU2020000110A CU20200110A CU20200110A7 CU 20200110 A7 CU20200110 A7 CU 20200110A7 CU 2020000110 A CU2020000110 A CU 2020000110A CU 20200110 A CU20200110 A CU 20200110A CU 20200110 A7 CU20200110 A7 CU 20200110A7
Authority
CU
Cuba
Prior art keywords
peptides
treatment
seq
respiratory infections
viral origin
Prior art date
Application number
CU2020000110A
Other languages
English (en)
Inventor
Pérez Karen Álvarez
Rico Ania Cabrales
Casanova Dionne Casillas
Cano Carlos Antonio Duarte
CAMA Viviana FALCÓN
Ortega Celia Berta Fernández
Pérez Hilda Elisa Garay
Nieto Gerardo Enrique Guillén
Rodríguez Silvio Ernesto Perea
González Carmen Laura Perera
SUÁREZ Anna Caridys RAMÍREZ
Moltó María Pilar Rodríguez
Gómez Raimundo Ubieta
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000110A priority Critical patent/CU20200110A7/es
Priority to CN202180086605.5A priority patent/CN116964073A/zh
Priority to EP21865363.2A priority patent/EP4268840A2/en
Priority to PCT/CU2021/050015 priority patent/WO2022135622A2/es
Priority to JP2023536568A priority patent/JP7758737B2/ja
Priority to MX2023007603A priority patent/MX2023007603A/es
Priority to CA3203026A priority patent/CA3203026A1/en
Priority to KR1020237023283A priority patent/KR20230124613A/ko
Priority to AU2021406354A priority patent/AU2021406354A1/en
Priority to US18/269,231 priority patent/US20250282828A1/en
Publication of CU20200110A7 publication Critical patent/CU20200110A7/es
Priority to ZA2023/06485A priority patent/ZA202306485B/en
Priority to JP2025135680A priority patent/JP2025176030A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>Péptidos que poseen una secuencia de aminoácidos que se selecciona del grupo compuesto por SEQ ID NO: 2 a SEQ ID NO: 20, así como composiciones farmacéuticas que comprenden dichos péptidos. Composición farmacéutica que comprende un péptido que posee una secuencia de aminoácidos identificada como SEQ ID NO: 1. También se revela una combinación de al menos un péptido de secuencia de aminoácidos identificada como SEQ ID NO: 1 a la SEQ ID NO: 20 con un medicamento antiviral.</p>
CU2020000110A 2020-12-23 2020-12-23 Péptidos para el tratamiento de infecciones respiratorias de origen viral CU20200110A7 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2020000110A CU20200110A7 (es) 2020-12-23 2020-12-23 Péptidos para el tratamiento de infecciones respiratorias de origen viral
MX2023007603A MX2023007603A (es) 2020-12-23 2021-12-21 Peptidos para el tratamiento de infecciones respiratorias de origen viral.
EP21865363.2A EP4268840A2 (en) 2020-12-23 2021-12-21 Cigb-210 and analogues for the treatment of respiratory infections of viral origin
PCT/CU2021/050015 WO2022135622A2 (es) 2020-12-23 2021-12-21 Péptidos para el tratamiento de infecciones respiratorias de origen viral
JP2023536568A JP7758737B2 (ja) 2020-12-23 2021-12-21 ウイルス起源の各感染症の治療のためのペプチド
CN202180086605.5A CN116964073A (zh) 2020-12-23 2021-12-21 用于治疗病毒来源的呼吸道感染的肽
CA3203026A CA3203026A1 (en) 2020-12-23 2021-12-21 Peptides for the treatment of respiratory infections of viral origin
KR1020237023283A KR20230124613A (ko) 2020-12-23 2021-12-21 바이러스 유래의 호흡기 감염을 치료하기 위한 펩타이드
AU2021406354A AU2021406354A1 (en) 2020-12-23 2021-12-21 Peptides for the treatment of respiratory infections of viral origin
US18/269,231 US20250282828A1 (en) 2020-12-23 2021-12-21 Peptides for the treatment of respiratory infections of viral origin
ZA2023/06485A ZA202306485B (en) 2020-12-23 2023-06-22 Peptides for the treatment of respiratory infections of viral origin
JP2025135680A JP2025176030A (ja) 2020-12-23 2025-08-18 ウイルス起源の各感染症の治療のためのペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000110A CU20200110A7 (es) 2020-12-23 2020-12-23 Péptidos para el tratamiento de infecciones respiratorias de origen viral

Publications (1)

Publication Number Publication Date
CU20200110A7 true CU20200110A7 (es) 2022-08-09

Family

ID=80683900

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000110A CU20200110A7 (es) 2020-12-23 2020-12-23 Péptidos para el tratamiento de infecciones respiratorias de origen viral

Country Status (11)

Country Link
US (1) US20250282828A1 (es)
EP (1) EP4268840A2 (es)
JP (2) JP7758737B2 (es)
KR (1) KR20230124613A (es)
CN (1) CN116964073A (es)
AU (1) AU2021406354A1 (es)
CA (1) CA3203026A1 (es)
CU (1) CU20200110A7 (es)
MX (1) MX2023007603A (es)
WO (1) WO2022135622A2 (es)
ZA (1) ZA202306485B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019338A1 (ru) * 2024-07-18 2026-01-22 Общество с ограниченной ответственностью "Альбоген" Пептиды с противовирусной активностью

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
AU2016259869A1 (en) * 2015-05-11 2017-11-30 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (Poly(I:C)) pea starch formulation for the prevention and/or treatment of upper respiratory tract infections

Also Published As

Publication number Publication date
WO2022135622A3 (es) 2022-09-22
EP4268840A2 (en) 2023-11-01
ZA202306485B (en) 2024-11-27
AU2021406354A1 (en) 2023-07-06
WO2022135622A2 (es) 2022-06-30
CA3203026A1 (en) 2022-06-30
AU2021406354A9 (en) 2024-10-24
MX2023007603A (es) 2023-07-10
US20250282828A1 (en) 2025-09-11
KR20230124613A (ko) 2023-08-25
JP7758737B2 (ja) 2025-10-22
CN116964073A (zh) 2023-10-27
JP2024500731A (ja) 2024-01-10
JP2025176030A (ja) 2025-12-03

Similar Documents

Publication Publication Date Title
CO2022011728A2 (es) Composiciones y usos de glp-1
BR112018075465A2 (pt) agentes antivirais de hepatite b
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
UY38059A (es) Heterociclos sustituidos como agentes antivirales
ECSP22076862A (es) Compuestos antivirales y métodos para la administración de los mismos
UY37997A (es) Agentes antivirales contra la hepatitis b
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
CO2017007293A2 (es) Dinucleótidos cíclicos útiles para el tratamiento de (inter alia) cáncer
UY37998A (es) Agentes antivirales contra la hepatitis b
AR065349A1 (es) Coagonistas del receptor de glucagon/glp-1
CL2012000715A1 (es) Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular.
PE20181176A1 (es) Composiciones biofarmaceuticas
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
FI3534939T3 (fi) Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi
CU20210088A7 (es) Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112018012044A2 (pt) bacteriófago pas-mup-1 de pasteurella multocida inovador e uso do mesmo para inibir a proliferação de pasteurella multocida
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
CO2024016693A2 (es) Péptido con actividad antimicrobiana
MX360206B (es) Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197.
JP2013542196A5 (es)
PE20121553A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria
CR20190249A (es) Constructos de vacuna y sus usos contrainfecciones causadas por staphylococcus
BR112021014640A8 (pt) Sais de sulcardina